Phase 3
Development Phase
1
Upcoming Catalysts
0
Historical Events
2
Regulatory Approvals
0 competitors in Cerebral Adrenoleukodystrophy (cALD)
View Full LandscapeTarget Indication
Cerebral Adrenoleukodystrophy (cALD)
Clinical Trial
NCT05819866Last updated: 7/23/2026
No patent data available. Pre-approval drugs may not have Orange Book listings.
Nezglyal
Nezglyal is indicated for the treatment of male ALD patients aged 2 years and older with brain lesions to delay progression of cerebral adrenoleukodystrophy (cALD).
Nezglyal
Nezglyal is indicated for the treatment of Cerebral Adrenoleukodystrophy (cALD) in males with Adrenoleukodystrophy (ALD) aged 2 to 12 years with non Gadolinium (Gd) enhancing lesions (i.e. Gd negative) in brain Magnetic Resonance Imaging (MRI), with a Neurological Functional Score (NFS) of 0 or 1.